Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)

by Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg B, Mertenskoetter T
Published 2009-05-01

Treatment of HIV-related primary central nervous system lymphoma with azt high dose, HAART, interleukin-2 and foscarnet in three patients

by Marretta L, Stocker H, Drauz D, Mueller M, Masuhr A, Dieckmann S, Wong V, Koch A, Grueneisen A, Arastéh K, Weiss R
Published 2011-05-01

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine

by Ellefsen-Lavoie K, Rockstroh J, Pollard R, Pantaleo G, Podzamczer D, Asmuth D, van Lunzen J, Arastéh K, Schürmann D, Peters B, Clotet B, Hardy D, Lazzarin A, Gatell J, Sommerfelt MA, Baksaas I, Wendel-Hansen V, Sørensen B
Published 2012-09-01